相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Noncovalent Wild-type-Sparing Inhibitors of EGFR T790M
Ho-June Lee et al.
CANCER DISCOVERY (2013)
CHEMICAL BIOLOGY Greasy tags for protein removal
Taavi K. Neklesa et al.
NATURE (2012)
HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR-Mutant Lung Cancers That Lack the Second-Site EGFRT790M Mutation
Ken Takezawa et al.
CANCER DISCOVERY (2012)
Activation of Multiple Proto-oncogenic Tyrosine Kinases in Breast Cancer via Loss of the PTPN12 Phosphatase
Tingting Sun et al.
CELL (2011)
BindingDB and ChEMBL: online compound databases for drug discovery
Anne Mai Wassermann et al.
EXPERT OPINION ON DRUG DISCOVERY (2011)
Using iTRAQ Combined with Tandem Affinity Purification to Enhance Low-Abundance Proteins Associated with Somatically Mutated EGFR Core Complexes in Lung Cancer
Eric B. Haura et al.
JOURNAL OF PROTEOME RESEARCH (2011)
Epithelial to Mesenchymal Transition in an Epidermal Growth Factor Receptor-Mutant Lung Cancer Cell Line with Acquired Resistance to Erlotinib
Kenichi Suda et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity
Theonie Anastassiadis et al.
NATURE BIOTECHNOLOGY (2011)
Comprehensive analysis of kinase inhibitor selectivity
Mindy I. Davis et al.
NATURE BIOTECHNOLOGY (2011)
An orthosteric inhibitor of the Ras-Sos interaction
Anupam Patgiri et al.
NATURE CHEMICAL BIOLOGY (2011)
Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90
Kamalika Moulick et al.
NATURE CHEMICAL BIOLOGY (2011)
Small-molecule hydrophobic tagging-induced degradation of HaloTag fusion proteins
Taavi K. Neklesa et al.
NATURE CHEMICAL BIOLOGY (2011)
DrugBank 3.0: a comprehensive resource for 'Omics' research on drugs
Craig Knox et al.
NUCLEIC ACIDS RESEARCH (2011)
Survival and Death Signals Can Predict Tumor Response to Therapy After Oncogene Inactivation
Phuoc T. Tran et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Lecia V. Sequist et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Targeting epidermal growth factor receptor: Central signaling kinase in lung cancer
Takeshi Yoshida et al.
BIOCHEMICAL PHARMACOLOGY (2010)
Inhibition of ALK, PI3K/MEK, and HSP90 in Murine Lung Adenocarcinoma Induced by EML4-ALK Fusion Oncogene
Zhao Chen et al.
CANCER RESEARCH (2010)
Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation
Martin L. Sos et al.
CANCER RESEARCH (2010)
Frequency of and variables associated with the EGFR mutation and its subtypes
Tomoaki Tanaka et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non-Small-Cell Lung Cancer
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced Non-Small-Cell Lung Cancer
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3
Thomas Fischer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
A chemical and phosphoproteomic characterization of dasatinib action in lung cancer
Jiannong Li et al.
NATURE CHEMICAL BIOLOGY (2010)
Characterizing Tyrosine Phosphorylation Signaling in Lung Cancer Using SH2 Profiling
Kazuya Machida et al.
PLOS ONE (2010)
Synthetic Lethal Screen of an EGFR-Centered Network to Improve Targeted Therapies
Igor Astsaturov et al.
SCIENCE SIGNALING (2010)
RNAither, an automated pipeline for the statistical analysis of high-throughput RNAi screens
Nora Rieber et al.
BIOINFORMATICS (2009)
Ligand-Dependent Platelet-Derived Growth Factor Receptor (PDGFR)-α Activation Sensitizes Rare Lung Cancer and Sarcoma Cells to PDGFR Kinase Inhibitors
Ultan McDermott et al.
CANCER RESEARCH (2009)
PEST family phosphatases in immunity, autoimmunity, and autoinflammatory disorders
Andre Veillette et al.
IMMUNOLOGICAL REVIEWS (2009)
An integrated workflow for charting the human interaction proteome: insights into the PP2A system
Timo Glatter et al.
MOLECULAR SYSTEMS BIOLOGY (2009)
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
Wenjun Zhou et al.
NATURE (2009)
Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources
Da Wei Huang et al.
NATURE PROTOCOLS (2009)
Applying mass spectrometry-based proteomics to genetics, genomics and network biology
Matthias Gstaiger et al.
NATURE REVIEWS GENETICS (2009)
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer.
Rafael Rosell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Oncogene Mutations, Copy Number Gains and Mutant Allele Specific Imbalance (MASI) Frequently Occur Together in Tumor Cells
Junichi Soh et al.
PLOS ONE (2009)
Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition
Anthony C. Faber et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance
Takeshi Shimamura et al.
CANCER RESEARCH (2008)
Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non-small cell lung cancer: An analytical database
Samuel Murray et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
A network solution
Adriano Henney et al.
NATURE (2008)
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
James Bean et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer
Klarisa Rikova et al.
CELL (2007)
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling
Ultan McDermott et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib, reveal novel kinase and nonkinase targets
Uwe Rix et al.
BLOOD (2007)
Suppressor of T-cell receptor signalling 1 and 2 differentially regulate endocytosis and signalling of receptor tyrosine kinases
Josipa Raguz et al.
FEBS LETTERS (2007)
Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling
K. Shtiegman et al.
ONCOGENE (2007)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities
Tiqing Liu et al.
NUCLEIC ACIDS RESEARCH (2007)
A common signaling cascade may underlie addiction to the Src, BCR-ABL, and EGF receptor oncogenes
Sreenath V. Sharma et al.
CANCER CELL (2006)
Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins
T Shimamura et al.
CANCER RESEARCH (2005)
TIM, a Dbl-related protein, regulates cell shape and cytoskeletal organization in a Rho-dependent manner
XZ Xie et al.
CELLULAR SIGNALLING (2005)
ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines
JA Engelman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
A uniform proteomics MS/MS analysis platform utilizing open XML file formats
Andrew Keller et al.
MOLECULAR SYSTEMS BIOLOGY (2005)
Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor
JL Marshall et al.
INVESTIGATIONAL NEW DRUGS (2005)
Immunoaffinity profiling of tyrosine phosphorylation in cancer cells
J Rush et al.
NATURE BIOTECHNOLOGY (2005)
Analysis of clathrin-mediated endocytosis of epidermal growth factor receptor by RNA interference
FT Huang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer
C Monnerat et al.
ANNALS OF ONCOLOGY (2004)
EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib
W Pao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways
R Sordella et al.
SCIENCE (2004)
Suppressors of T-cell receptor signaling Sts-1 and Sts-2 bind to Cbl and inhibit endocytosis of receptor tyrosine kinases
K Kowanetz et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Functional organization of the yeast proteome by systematic analysis of protein complexes
AC Gavin et al.
NATURE (2002)
Induction of human Cdc37 in prostate cancer correlates with the ability of targeted Cdc37 expression to promote prostatic hyperplasia
L Stepanova et al.
ONCOGENE (2000)
分享论文
